# Mastoid Obliteration After Canal Wall Down Mastoidectomy Using Tissue Engineering Approaches with Polymers, Mesenchymal Stem Cells, and Bioactive Molecules: A Systematic Review

**Authors:** Kyung Hoon Sun, Cheol Hee Choi, Minseong Kim, Chul Ho Jang

PMC · DOI: 10.3390/bioengineering13030305 · Bioengineering · 2026-03-05

## TL;DR

This review explores tissue engineering methods for mastoid obliteration after surgery, showing promise in animal studies but limited clinical evidence.

## Contribution

The study systematically evaluates tissue engineering approaches for mastoid obliteration, highlighting polymer-MSC constructs as a novel regenerative strategy.

## Key findings

- Polymer-supported MSC constructs showed consistent osteogenic enhancement in animal models.
- Clinical evidence is limited to small case series using PRP-based approaches.
- Preclinical data suggest regenerative potential, but more clinical studies are needed.

## Abstract

Background: Mastoid obliteration following canal wall down mastoidectomy reduces cavity-related morbidity. Conventional obliteration materials act primarily as passive fillers, whereas tissue engineering (TE) strategies aim to achieve biologically active bone regeneration. Methods: This systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from January 2010 to December 2025. Studies evaluating tissue engineering-assisted mastoid obliteration involving growth factors, mesenchymal stem cells, polymer scaffolds, or 3D-printed constructs were included. Results: Fifteen studies met inclusion criteria (12 preclinical and three clinical). Polymer-supported MSC constructs demonstrated the most consistent osteogenic enhancement in animal models. Clinical evidence remains limited to small PRP-based case series. Conclusions: Preliminary evidence suggests that tissue engineering-assisted mastoid obliteration has regenerative potential, although the evidence is limited by predominantly preclinical data and a moderate-to-high risk of bias. Standardized outcome measures and well-designed prospective clinical studies are required to confirm long-term safety and efficacy.

## Full-text entities

- **Diseases:** Mastoid Obliteration (MESH:D008417)
- **Chemicals:** Polymer (MESH:D011108)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023967/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13023967/full.md

## References

77 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023967/full.md

---
Source: https://tomesphere.com/paper/PMC13023967